{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:37:19Z","timestamp":1787071039404,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To find out the epidemiological factors and oncology treatment outcome in human immunodeficiency virus-positive cancer cervix patients (HPCCP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>After institutional ethics committee approval, hospital case records of HPCCP registered at the radiation oncology department from January 2011 to December 2018 were retrospectively studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The case records of 22 eligible HPCCP were studied. Median age at presentation was 42.5 years. 90.90% of the patients were below 55 years of age. The duration of symptom was &lt;3 months in 63.64% of patients. 68.18% of the patients were FIGO Stage III. Only 11 patients completed the planned treatment. Total target equivalent dose of 2 Gy per fraction delivered was 66 Gy. Seven patients had complete response. Four patients had local recurrence. Median disease-free and overall survival was 27 (14\u201338) and 18 months (2\u201348), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>HPCCP present at relatively early age and advanced stage despite short symptom duration. Poor patient compliance and treatment alteration have led to suboptimal outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_230_20","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T07:32:56Z","timestamp":1629444776000},"page":"1537-1540","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Oncology treatment outcome in human immunodeficiency virus-positive cancer cervix patients"],"prefix":"10.4103","volume":"18","author":[{"given":"Chaitali Manohar","family":"Waghmare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arya","family":"Bhanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant J","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana Shailendra","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-13-20241021","first-page":"1","article-title":"1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults","volume":"41","author":"Castro","year":"1992","journal-title":"MMWR Recomm Rep"},{"key":"R5-13-20241021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/ijgc-00009577-200501000-00001","article-title":"Double jeopardy: HIV and cervical cancer in Indian women","volume":"15","author":"Sahasrabuddhe","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"R6-13-20241021","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0090-8258(90)90077-X","article-title":"Human immunodeficiency virus infection and cervical neoplasia","volume":"3893","author":"Miaman","year":"1990","journal-title":"Gynecol Oncol"},{"key":"R7-13-20241021","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brachy.2011.07.002","article-title":"American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: High-dose-rate brachytherapy","volume":"11","author":"Viswanathan","year":"2012","journal-title":"Brachytherapy"},{"key":"R8-13-20241021","first-page":"CD002225","article-title":"Concomitant chemotherapy and radiation therapy for cancer of uterine cervix","volume":"20","author":"Green","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"R9-13-20241021","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2018.08.038","article-title":"Five-year overall survival following chemoradiation among HIV-positive and HIV-negative patients with locally advanced cervical carcinoma in a South African cohort","volume":"151","author":"Simonds","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R10-13-20241021","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/IGC.0000000000000441","article-title":"HIV status and acute haematological toxicity among patients with cervix cancer undergoing radical chemoradiation","volume":"25","author":"Simonds","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"R11-13-20241021","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ijgo.12611","article-title":"FIGO Cancer Report-Cancer of cervix uteri","volume":"143","author":"Bhatla","year":"2018","journal-title":"Int J Gynecol Obstet"},{"key":"R12-13-20241021","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guidelines (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Europ J Cancer"},{"key":"R15-13-20241021","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0090-8258(90)90077-X","article-title":"Human immunodeficiency virus infection and cervical neoplasia","volume":"38","author":"Maiman","year":"1990","journal-title":"Gynecol Oncol"},{"key":"R16-13-20241021","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.radonc.2004.11.006","article-title":"HIV infection and invasive cervical cancer, treatment with radiation therapy: Toxicity and outcome","volume":"74","author":"Srivastava","year":"2005","journal-title":"Radiother Oncol"},{"key":"R18-13-20241021","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1200\/JCO.2016.67.9613","article-title":"HIV Infection and survival among women with cervical cancer","volume":"34","author":"Dryden-Peterson","year":"2016","journal-title":"J Clin Oncol"},{"key":"R19-13-20241021","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijrobp.2018.01.067","article-title":"Impact of human immunodeficienct virus infection on survival and acute toxicities from chemoradiation therapy for cervical cancer patients in a limited resource setting","volume":"101","author":"Grove","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R20-13-20241021","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/cncr.26639","article-title":"Completion and earl response to chemoradiation among human immunodeficiency virus infection (HIV) positive and HIV negative patients with locally advanced cervical carcinoma in South Africa","volume":"118","author":"Simonds","year":"2012","journal-title":"Cancer"},{"key":"R21-13-20241021","first-page":"1645","article-title":"Outcome of cervical cancer among HIV infected and HIV uninfected women treated at the Brazilian National Institute of Cancer","volume":"20","author":"Ferreria","year":"2017","journal-title":"AIDS"},{"key":"R22-13-20241021","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.gore.2017.07.009","article-title":"Cervical cancer control in HIV-infected women: Past, present and future","volume":"21","author":"Ghebre","year":"2017","journal-title":"Gynecol Oncol Rep"},{"key":"R23-13-20241021","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0360-3016(98)00528-8","article-title":"The significance of pre treatment CD4 count on the outcome and treatment tolerance of HIV positive patients with anal cancer","volume":"44","author":"Welton","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_230_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:39Z","timestamp":1787067639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_230_20"}},"subtitle":["Where we are and what we achieved?"],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_230_20","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}